UBS Group
ACLX

UBS Group’s Arcellx ACLX Stock Holding History

UBS Group’s Portfolio ACLX Stock Details ACLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4M Sell
194,709
-121,903
-39% -$10.8M ﹤0.01% 2473
2025
Q4 		$20.6M Buy
316,612
+127,236
+67% +$10.2M ﹤0.01% 2563
2025
Q3 		$15.5M Buy
189,376
+40,459
+27% +$2.91M ﹤0.01% 2846
2025
Q2 		$9.81M Sell
148,917
-60,655
-29% -$3.78M ﹤0.01% 3095
2025
Q1 		$13.7M Buy
209,572
+2,033
+1% +$138K ﹤0.01% 2725
2024
Q4 		$15.9M Buy
207,539
+150,176
+262% +$13M ﹤0.01% 2578
2024
Q3 		$4.79M Sell
57,363
-6,214
-10% -$414K ﹤0.01% 3116
2024
Q2 		$3.51M Sell
63,577
-39,904
-39% -$2.17M ﹤0.01% 3195
2024
Q1 		$7.2M Buy
103,481
+6,436
+7% +$408K ﹤0.01% 2580
2023
Q4 		$5.39M Buy
97,045
+47,613
+96% +$2.15M ﹤0.01% 2709
2023
Q3 		$1.77M Sell
49,432
-72,075
-59% -$2.48M ﹤0.01% 3557
2023
Q2 		$3.84M Buy
121,507
+120,515
+12,149% +$4.61M ﹤0.01% 2841
2023
Q1 		$30.6K Sell
992
-1,449
-59% -$44K ﹤0.01% 6784
2022
Q4 		$75.6K Sell
2,441
-184,236
-99% -$4.23M ﹤0.01% 6364
2022
Q3 		$3.5M Sell
186,677
-9,980
-5% -$191K ﹤0.01% 2666
2022
Q2 		$3.56M Sell
196,657
-29,604
-13% -$382K ﹤0.01% 2660
2022
Q1 		$3.17M Buy
+226,261
New +$3.78M ﹤0.01% 3008

Other funds holding ACLX

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UBS Group's ACLX Position: Q1 2026 in Review

UBS Group reduced its Arcellx (ACLX) stake by 39% in Q1 2026, selling an estimated $10.8M and leaving 194,709 shares worth $22.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

UBS Group first reported a position in ACLX in Q1 2022 and has held it in 17 quarters since. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

  • UBS Group held 194,709 shares of Arcellx worth $22.4M as of Q1 2026.
  • UBS Group sold 121,903 Arcellx shares in Q1 2026, an estimated $10.8M.
  • Arcellx made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #2473 holding.
  • UBS Group first reported a position in Arcellx in Q1 2022 and has held it in 17 quarters since.
  • 239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.